Brand-name drug
Foundayo price, strengths & recalls
Brand of orforglipron (generic)
Pharmacies pay $627.48 for 30 tablets of Foundayo 0.8 mg tablet this week, and from $624.85 to $632.28 across its 6 priced strengths and forms. Its official label last changed on August 13, 2026.
Brand- Fair cash price
- $732.10
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Foundayo price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.8 mg tablet Brand | $20.92 | $627.48 / 30 tablets |
| 2.5 mg tablet Brand | $20.89 | $626.78 / 30 tablets |
| 5.5 mg tablet Brand | $20.88 | $626.34 / 30 tablets |
| 9 mg tablet Brand | $20.92 | $627.49 / 30 tablets |
| 14.5 mg tablet Brand | $20.83 | $624.85 / 30 tablets |
| 17.2 mg tablet Brand | $21.08 | $632.28 / 30 tablets |
The lowest cost per tablet is 14.5 mg tablet at $20.83. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Foundayo vs generic orforglipron
There is no generic version of Foundayo on the market yet. Its last listed patent or exclusivity runs to September 26, 2037 - generics often follow, though court cases and settlements can move the date either way.
GenericOrforglipron pricesSupply status: shortages & recalls
What people paid for Foundayo
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO.FOUNDAYO (orforglipron) tablets, for oral useInitial U.S. Approval: 2026
WARNING: RISK OF THYROID C-CELL TUMORS
In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)]. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].
FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of FOUNDAYO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with FOUNDAYO [see Contraindications (4), Warnings and Precautions (5.1)].
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents (13.1). While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined (5.1, 13.1).
FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA220934 · Eli Lilly And Co
- First approved
- April 1, 2026 (0 years ago)
- Latest approved change
- August 4, 2026
- Approved label
- PDF, Aug 4, 2026
- Generic makers
- None on the market
- Last patent listed
- September 26, 2037
- Exclusivity ends
- April 1, 2031
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Foundayo questions
How much does foundayo cost without insurance?
Pharmacies pay about $627.48 for 30 tablets of foundayo 0.8 mg tablet ($20.92 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $732.10. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Foundayo?
Yes: orforglipron. Compare orforglipron prices.
Is foundayo in shortage?
No shortage is reported for foundayo right now. We check the national shortage list every day.
Has foundayo been recalled?
No recalls are on record for foundayo.
When did the foundayo label last change?
The official label was last updated on August 13, 2026 (version 10). See what changed.
Talk about foundayo
No comments yet. Questions, tips, what worked for you - start the conversation.